Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model [PDF]
, 2016 Patients with stable coronary artery disease (CAD) constitute a heterogeneous group in which the treatment benefits by angiotensin-converting enzyme (ACE)-inhibitor therapy vary between individuals.
Akkerhuis, KM +14 more
core +1 more source
Mitigation of Radiation Induced Pulmonary Vascular Injury by Delayed Treatment with Captopril [PDF]
, 2012 Background and Objective: A single dose of 10 Gy radiation to the thorax of rats results in decreased total lung angiotensin-converting enzyme (ACE) activity, pulmonary artery distensibility and distal vascular density while increasing pulmonary ...
Fish, Brian L. +5 more
core +2 more sources
ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury [PDF]
, 1997 Objective: Polymorphonuclear leukocytes (PMN), retained in the microvascular bed, can contribute to postischemic myocardial reperfusion injury. Since a beneficial effect of ACE-inhibition on reperfusion injury has been reported, we investigated the ...
Becker, Bernhard F. +6 more
core +1 more source
Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure [PDF]
, 2018 Objectives: The purpose of this study was to evaluate the renal effects of sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Claggett, Brian +14 more
core +9 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019 Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of reducing cardiovascular mortality in the PARADIGM‐HF (Prospective ...
Yiwen Wang +5 more
doaj +1 more source
Emerging pharmacological treatments to prevent abdominal aortic aneurysm growth and rupture [PDF]
, 2015 Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the management of cardiovascular diseases, there currently is no established ...
Fraga-Silva, Rodrigo +2 more
core +2 more sources
Drug treatment of hypertension: focus on vascular health [PDF]
, 2016 Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart
Cameron, Alan C. +2 more
core +1 more source
Effect of amaranth proteins on the RAS system: In vitro, in vivo and ex vivo assays [PDF]
, 2020 The aim of this work was to analyse the hypotensive effect of amaranthprotein/peptides on spontaneously hypertensive rats (SHR). The mechanism of action of these peptides was studied in vivo and ex vivo.
Aphalo, Paula +4 more
core +2 more sources
Novelty in BiomedicineBackground: To investigate differences in disease severity and outcomes among COVID-19 patients with a history of hypertension using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive drugs.
Seyedpouzhia Shojaei +7 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene +16 more
doaj +1 more source